Diverse cellular architecture of atherosclerotic plaque derives from clonal expansion of a few medial SMCs

Kevin Jacobsen,1,2 Marie Bek Lund,1 Jeong Shim,1 Stine Gunnersen,1 Ernst-Martin Füchtbauer,3 Mads Kjolby,4 Laura Carramolino,2 and Jacob Fog Bentzon1,2

1Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 2Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. 3Department of Molecular Biology and Genetics and 4Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Fibrous cap smooth muscle cells (SMCs) protect atherosclerotic lesions from rupturing and causing thrombosis, while other plaque SMCs may have detrimental roles in plaque development. To gain insight into recruitment of different plaque SMCs, we mapped their clonal architecture in aggregation chimeras of eGFP+Apoe−/− and Apoe−/− mouse embryos and in mice with a mosaic expression of fluorescent proteins in medial SMCs that were rendered atherosclerotic by PCSK9-induced hypercholesterolemia. Fibrous caps in aggregation chimeras were found constructed from large, endothelial-aligned layers of either eGFP+ or nonfluorescent SMCs, indicating substantial clonal expansion of a few cells. Similarly, plaques in mice with SMC-restricted Confetti expression showed oligoclonal SMC populations with little intermixing between the progeny of different medial SMCs. Phenotypes comprised both ACTA2+ SMCs in the cap and heterogeneous ACTA2− SMCs in the plaque interior, including chondrocyte-like cells and cells with intracellular lipid and crystalline material. Fibrous cap SMCs were invariably arranged in endothelium-aligned clonal sheets, confirming results in the aggregation chimeras. Analysis of the clonal structure showed that a low number of local medial SMCs partake in atherosclerosis and that single medial SMCs can produce several different SMC phenotypes in plaque. The combined results show that few medial SMCs proliferate to form the entire phenotypically heterogeneous plaque SMC population in murine atherosclerosis.

Introduction

Atherosclerotic plaque smooth muscle cells (SMCs) have traditionally been identified in atherosclerotic plaques by detection of contractile myofilaments or the proteins contained herein (e.g., smooth muscle α-actin [ACTA2] and smooth muscle myosin heavy chain [MYH11]). Such contractile SMCs reside predominantly in the superficial parts of lesions and, together with the fibrous tissue matrix they produce, make up the fibrous cap. Recent studies tracking the fate of arterial SMCs in murine and human atherosclerosis have shown that plaques also contain sizeable populations of SMCs without contractile proteins (1–3). The phenotypes and functional repertoire of these modulated SMCs are still not well delineated.

Thin fibrous caps render plaques vulnerable to rupture and are the underlying cause of 60%–80% of lethal coronary thrombi (4, 5). Previous research has implicated replicative exhaustion and resultant loss of cap SMCs as a contributing cause to cap degradation. Human fibrous cap SMCs bear markers of cellular senescence, have reduced rates of mitosis, and have shorter telomeres than SMCs of the neighboring normal vessel wall (6). In mice, protecting SMCs against replicative senescence increases cap thickness (7).

Recent attempts to address this question in human arterial specimens have been inconclusive. Analyses of X chromosome inactivation in homogenized microdissected arteries have indicated that ACTA2+ SMC-rich regions, including fibrous cap SMCs, contain large clonal populations (9). These analyses,
however, could not resolve whether the apparent clonal SMC expansion occurred during embryonic development, body growth, or atherogenesis, with the problem being that the normal arterial intima and media — from where plaque SMCs were recruited — also appeared to consist of large coherent populations of SMCs derived from single embryonic founder cells (9, 10).

In the present study, we use experimental atherosclerosis models to gain insight into the development and clonal architecture of the fibrous cap, as well as the rest of the SMC population. We show that the normal murine aorta has a small SMC patch size allowing for investigation of clonal SMC expansion in aggregation chimeras, and we use chimeras and mice with a randomly recombining fluorescent transgene to show that plaque SMCs, including fibrous cap, chondrocyte-like, and lipid-filled SMCs, undergo significant clonal expansion during plaque development. Furthermore, we show that the fibrous cap population has a sheet-like, endothelium-aligned architecture indicative of an endothelium-cued recruitment process.

**Results**

**Clonal analysis in chimeric Apoe−/− mice.** We examined clonal relationships of ACTA2+ fibrous cap SMCs in mouse chimeras created by aggregating 8-cell embryos from matings of eGFP+Apoe−/− and Apoe−/− mice (n = 9) (Figure 1A). The mice were kept on chow until 10 months to develop atherosclerosis. By initial analysis of the myocardium, 4 mice were found to be balanced eGFP+Apoe−/− ↔ Apoe−/− chimeras. The others had either no (n = 3) or nearly ubiquitous (n = 2) eGFP expression in the myocardium and were likely generated by aggregation of 8-cell embryos of the same genotype (Apoe−/− ↔ Apoe−/− and eGFP+Apoe−/− ↔ eGFP Apoe−/−).

The clonal architecture of the aorta has not been previously reported for mice. Analysis of ACTA2+ SMCs in the aortic media of aggregation chimeras showed that the size of patches, defined as groups of contiguous cells of the same color, was small, with cells of the less common genotype interspersed between the others in groups comprising only a few cell profiles. This was the case in both the cross-sectional (aortic root) and in the longitudinal (aortic arch) direction (Figure 1, B and C). In the positive control eGFP Apoe−/− ↔ eGFP Apoe−/− mice, all medial SMCs expressed eGFP, albeit with some heterogeneity in expression levels (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.95890DS1).

The clonal pattern of the murine aortic media is consistent with the developmental processes described for the murine pulmonary artery, where intermixing of cells occurs during recruitment and differentiation of SMCs along the nascent endothelium (11). Curiously, this is very different from the pattern reported for human aortas and coronary arteries, proposed to have large coherent patches of SMCs deriving from the same embryonic ancestor cells (9, 10). Importantly, the small patch size of eGFP+ and nonfluorescent SMCs in the media allowed us to analyze for SMC clonal expansion during the formation of atherosclerotic plaques. Both in the aortic root and inner aortic arch, we found clear evidence that plaque ACTA2+ fibrous cap SMCs are an oligoclonal population, consisting of coherent sheets of cells with the same genotype. The patch size of ACTA2+ SMCs in the plaque was considerably larger than seen in the arterial media in all of the 4 chimeras examined (Figure 1, B and C). Combined with existing evidence that medial SMCs are the precursors of ACTA2+ SMCs in mouse atherosclerosis (1–3), this indicates that plaque ACTA2+ SMCs arise by substantial proliferation of a limited number of medial SMCs. When fibrous caps contained more than one genotype of cells, they were often seen arranged in a layered architecture.

**Medial SMC fate mapping in mosaic mice.** The analysis of aggregation chimeras left several questions unanswered. First, it only allowed the identification of SMCs expressing ACTA2, which has high specificity but low sensitivity for the SMC lineage in atherosclerotic plaques (1–3). Second, it did not provide direct tracing of cell origin back to medial SMCs. Third, analysis of SMC migration and proliferation in Apoe−/− mice was potentially biased by the lack of APOE, which has direct inhibitory effects on SMC migration and proliferation (12). To overcome the first 2 limitations, we turned to Myh11-CreERT2 Confetti mice. The Myh11-CreERT2 line has previously been shown to provide inducible CRE recombinase activity that is highly specific to SMCs with no detectable recombination in other tissues or circulating cells (13, 14). The Confetti transgene harbors the coding sequence of 4 fluorescent proteins that can be randomly recombined under the influence of CRE to give expression of membrane-bound CFP (mCFP), nuclear GFP (nGFP), yellow fluorescent protein (YFP), or red fluorescent protein (RFP) (15). The combination of the 2 transgenes, thus, allowed us to track the progeny of single medial SMCs during the development of atherosclerosis, irrespective of phenotypic changes they might undergo. To meet the third limitation, we induced atherosclerosis without
deleting Apoe with adeno-associated virus encoding a murine gain-of-function mutant (D377Y) of PCSK9 in hepatocytes, which renders the mice functionally LDL receptor deficient and severely hypercholesterolemic when fed a high-fat diet (16).

We induced CRE recombinase activity between 6 and 8 weeks of age in Myh11-CreERT2 Confetti mice and in Myh11-CreERT2 littermate controls. Three to 5 days after the last injection, when stable mosaic expression of fluorescent proteins in medial SMCs had been achieved, atherosclerosis was initiated with an injection of rAAV8-D377Y-PCSK9 and high-fat diet.

Plasma cholesterol levels and the development of atherosclerosis at 12, 24, and 36 weeks after the recombinant adeno-associated virus (rAAV) injection are shown in Figure 2, A and B. The total cholesterol levels achieved were lower and the variation higher than previously reported by us for the rAAV8-D377Y-PCSK9 technique (16). This may have been due to the close temporal proximity of the liver-directed rAAV8-D377Y-PCSK9 gene transfer and the series of hepatotoxic tamoxifen injections, since other work conducted by us concurrently (unpublished observations, 2015), in which rAAV8-D377Y-PCSK9 treatment was deferred 1 month after the last tamoxifen injection, led to levels and variation of cholesterol similar to our previous report (16).

No significant effects of the Confetti transgene on plasma cholesterol levels were noted, but Myh11-CreERT2 Confetti mice developed significantly less atherosclerosis compared with similarly treated Myh11-CreERT2 littermates (Figure 2B).
Recombination efficiencies, determined in undiseased segments in serial sections of the aortic root at 12 weeks of age, were 56.3% ± 10.4% (mean ± SD) (Figure 2C). The most common outcome of recombination was expression of RFP, followed by YFP and mCFP, whereas nGFP expression occurred infrequently (Figure 2D). Our observations are consistent with the reported lower frequency of recombination events involving the LoxP site preceding the nGFP cassette (https://www.jax.org/strain/017492). The less than complete recombination aids clonal analysis by lowering the chance that the progeny of different medial SMCs of the same color will occupy the same region of plaque. This is particularly the case for mCFP, which is present in only 9.0% of medial SMCs, whereas RFP with a frequency in medial SMCs of 30.5% should be interpreted more carefully, as discussed further below, because of the higher chance that 2 independent SMCs moving into atherosclerosis could have the same color. Consistent with previous reports on Myh11-CreERT2 mice (13, 14), we did not detect recombination, except in the arterial media of the aorta and neighboring small arteries and arterioles.

Recruitment of plaque SMCs. To focus our clonal analysis on progressed lesions containing SMCs, rather than early foam cell lesions, we selected the 10 mice with most atherosclerosis at 12, 24, and 36 weeks for further analysis. In each, we examined serial sections, spaced at 200 μm and covering the entire aortic root plaques. Figure 3, A and B, depicts lesion volume and cellularity in each coronary sinus; they are analyzed individually, since they represent separate atherogenic processes. Plaque development was much faster in the left and noncoronary than the right coronary sinus. A decline in cellularity (nuclei per mm² in serial sections) was notable over time, which — unlike plaque volume — showed no differences between sini (Figure 3B). Recruitment of fluorescent plaque SMCs followed the pattern of plaque growth with a wave of SMC recruitment in the left and noncoronary sinus between 12 and 24 weeks of plaque development, but this was not accomplished until after 24 weeks in the right coronary sinus (Figure 3C). Overall, our analysis encompassed approximately 2,500 plaque SMCs.

Clonal architecture of plaque SMCs. The pattern of fluorescent protein expression in plaque SMCs was substantially different from the single-cell mosaic configuration of the arterial media. Rather than being individual cells migrating into plaques from the media, the vast majority of SMCs belonged to large same-color cell patches occupying separate parts of the plaque (Figure 4). Figure 5A illustrates the organization of the fluorescent plaque SMC population at each time point. We found 133 SMC patches (1.5% nGFP, 17.3% mCFP, 35.3% YFP, 45.9% RFP). In 6 cases, 2 patches of different colors were overlapped, giving an area with a mixture of SMCs of 2 colors (Figure 4D). The distribution of patch colors was not different from the distribution of colors among medial SMCs (χ² test, P = 0.14).

The number of SMC patches increased from 12–24 weeks but was not significantly different between 24 and 36 weeks of plaque development (Figure 5B). There was a trend toward larger patch size at 36 weeks.
compared with 24 weeks and 12 weeks, but the difference was not statistically significant ($P = 0.06$, 1-way ANOVA, log-transformed data) (Figure 5C).

The number of fluorescent SMC patches divided by the average percentage of fluorescent cells in the media (56.3%) is a crude estimate of the number of medial SMCs that contribute to the plaque SMC population in the aortic root. For the 12-, 24-, and 36-week time points, this number was $2.1 \pm 2.4$, $10.2 \pm 5.3$, and $11.6 \pm 7.3$ SMCs, respectively. Importantly, these numbers could be both over- and underestimations of true values. They would be overestimations if progeny of single founder cells in some cases had split up and given rise to more than one patch, and they would be underestimations if SMC patches were sometimes derived from several founder cells.

Since only 9.0% of medial SMCs were mCFP, it is unlikely that coherent mCFP collections originated, except in rare instances, from several founder cells, considering that 2 medial SMCs recruited to the same region of plaque would be both mCFP in only $< 1\%$ of cases. Moreover, since patch size was not significantly different among different colors (1-way ANOVA, log-transformed, $P = 0.13$), the other-colored patches were also consistent with such single-cell origin. Having said that, inspection of the distribution of patch sizes of each color suggested that the largest RFP+ patches were indeed outliers and likely the progeny of more than one RFP founder cell (Supplemental Figure 2). This was consistent with the higher percentage of RFP+ cells in the media (30.5%) and, thus, the higher chance of 2 or 3 neighboring SMC clonal populations being RFP (9.3% and 2.8%, respectively). However, this would not have a significant impact on our estimates. Interpreting the largest 4 RFP patches (all found at 36 weeks) as the result of 2 founders each increased the estimate for 36 weeks to $12.3 \pm 8.3$ SMCs. Furthermore, although our serial sampling density at every 200 $\mu$m allowed us to miss single or small groups of SMCs, we would be unlikely to miss larger groups. The combined data, thus, showed that not only ACTA2+ cap SMCs, but all plaque cells of SMC lineage, are derived from a very limited number of medial SMCs undergoing coherent oligoclonal proliferation.

**Fibrous caps consist of sheet-like clonal populations.** Plaque SMCs labeled with Confetti fluorescence markers exhibited clearly heterogenous phenotypes. Fibrous cap SMCs, defined as SMCs associated with the endothelium, were present in 24 lesions (17 mice). Consistent with our findings in Apoe--/-- aggregation chimeras, fibrous caps were organized in sheet-like, same-colored patches, often spanning several consecutive serial sections (Figure 6, A and B). Immunostaining, performed after fluorescence microscopy, showed that these cells were ACTA2+, whereas SMCs in the interior of lesions were ACTA2 (Figure 6C). Nonfluorescent ACTA2+ cap SMCs were also often present, consistent with the less than complete recombination of the Confetti transgene in the arterial media.

**Other plaque SMC phenotypes.** In addition to ACTA2+ cap SMCs, 2 types of SMC phenotypes were readily identified in the interior of lesions. Large, often rounded cells, typically negative for ACTA2 (Figure 6C) and presumable similar to those that have previously been described as macrophage-like by other research groups (2, 14) were often abundant in lesions. Many of these cells had a foamy appearance of the cytoplasm especially recognizable in SMCs with cytoplasmic fluorescence (RFP or YFP) (Figure 7, A and B, and Figure 4A). In contrast with previous reports in Apoe--/-- mice (2, 14), we did not find the macrophage...
markers LGALS3 or CD68 expressed in SMCs (Figure 7C and Supplemental Figure 3), but laser reflection microscopy showed that foamy SMCs often contained reflective material (Figure 7D), and subsequent Oil Red O staining revealed that the majority had lipid accumulation (Figure 7, E–G).

Fluorescent chondrocyte-like cells were seen in a subset of lesions identified by their round morphology, expression of the chondrogenic transcription factor SOX9, and embedment in rich extracellular matrix (Figure 8). The identification of these cells confirms a previous lineage tracking study showing that this common plaque cell type is, at least partly, SMC derived (17) and extends it by showing that such areas of chondroid metaplasia typically represent the clonal progeny of a single medial SMC.

An important question is whether different SMC phenotypes are progeny of separate sublineages of medial SMCs. To address this, we focused on lesions that contained fluorescent SMCs of at least 2 of the 3 phenotypes described above. In 23 cases, we found that fluorescent SMCs of different phenotypes were part of a common patch (see examples in Figure 7A and Figure 8E), whereas there were only 8 lesions where different phenotypes in the plaque also belonged to differently colored patches. It is possible that some same-colored patches with 2 SMC phenotypes could be derived by 2 medial SMCs of the same color. However, their frequency very significantly exceeded the expected values under the hypothesis that 2 precursors are always needed to produce 2 different phenotypes ($P = 0.0001$, 2-tailed binomial test), which can be calculated from the distribution of colors in medial SMCs. Our findings were, thus, not compatible with the idea that different SMC phenotypes are always derived from different medial cells, and they show that single, differentiated medial SMCs can contribute to several different SMC phenotypes in plaques.

**Discussion**

Delineation of the clonal architecture of the SMC population in atherosclerosis provides important framework for understanding recruitment, fate, and function of SMCs in plaque progression and vulnerability. Here, we used aggregation chimeras and a randomly recombining transgene in 2 different atherosclerosis
models to achieve this goal. We found that fibrous caps are built from sheets of clonally expanded progeny of single medial SMCs. As part of our approach, we also describe the patterning of the murine aortic media; we demonstrate that not only cap SMCs, but also modulated SMCs in the plaque interior, are oligoclonal cell populations derived from few medial SMCs; and we demonstrate that the plaque SMC lineage in mice includes lipid-accumulating cells.

**Fibrous cap formation.** The architecture of the fibrous cap, clear in both aggregation chimeras and Myh11-CreERT2 Confetti mice, indicates an ordered process separate from the recruitment of the rest of plaque SMCs. Its often layered structure bears resemblance to the endothelium-cued development of the arterial media (18), but its clonal relationships are different. In contrast to the small patch size of the aortic media, caps were constructed by large layers of clonally expanded medial SMCs.

We speculate that the difference in the clonal structure of cap and medial SMCs, rather than reflecting different SMC recruitment mechanisms, may result from the different conditions under which the naked endothelium recruits its supporting SMC layers. In early murine atherosclerosis, the endothelium lose arterial media contact by the interpositioning of macrophage foam cells. Since the potential signals involved in SMC recruitment (e.g., PDGF signaling or direct cell contact, refs. 11, 18) can only traverse short distances, SMCs can initially only be recruited from the shoulder regions and subsequently only from progeny of the first recruited cell or cells. This is a marked difference from the development of media where the naked endothelium is surrounded by undifferentiated mesenchymal cells.

This difference may not necessarily apply to human arteries, especially at atherosclerosis-prone sites where the normal arterial intima and early atherosclerotic lesions already contain local intimal SMCs (19). These cells represent an alternative source of SMC recruitment for the cap and the rest of the plaque that is not present in mice. On the other hand, human intimal thickenings could themselves already be formed by oligoclonal expansion, leading to the same end result as described here. It will be important to revisit studies of SMC clonal relationships in humans with cellular resolution techniques to shed light on the clonal organization of arterial SMCs during artery development, intimal thickening, and plaque formation, but such studies are technically challenging.

If our findings in the mouse holds true for human atherosclerosis, one may speculate that the development of replicative senescence in cap SMCs is a direct consequence of the way that the cap is formed, rather than merely the result of continuing damage and cell replenishment alone. Unfortunately, mouse models of atherosclerosis are not well suited to address this question because cap SMCs do not undergo senescence in mice, possibly because of their extremely long telomeres (20).
Clonality and phenotype of non-cap SMCs. Our studies in mosaic Confetti mice allowed identification of several highly modulated SMCs in plaque interior and showed that the far majority of these cells also were part of sizeable clonal populations. This identifies SMC proliferation, rather than SMC migration, as the quantitatively dominant mechanisms underlying SMC accumulation in atherosclerosis, and it distinguishes the process from other vascular pathologies, e.g., the injured rat carotid artery, where nondividing, migrating SMCs contribute sizably to neointima formation (21).

While we were finalizing our analysis, Chappell et al. reached a similar conclusion based on a comprehensive analysis of the clonal structure of SMCs in Myh11-CreER<sup>T2</sup> Confetti Apoe<sup>–/–</sup> mice after 16–19 weeks of high-fat diet (22). The reported clonal structure in that experiment was, however, simpler than the one we found, with the far majority of plaques only containing SMCs of 1 or 2 Confetti colors in the setting of a higher medial SMC recombination efficiency (70%–95% medial SMCs) (for similar analysis of our data see Supplemental Figure 4). The reason for this difference could potentially lie in the lack of inhibitory effect of APOE on SMC proliferation in the Apoe<sup>–/–</sup> background. It may also be explained by other differences between models, time points, and arterial locations. The effect of the Confetti transgene on the atherosclerotic process or the particular architecture of the fibrous cap was not analyzed directly in the paper by Chappell et al. (22). More precise estimates of the number of medial SMCs that goes into forming the plaque SMC population in different atherosclerosis models and at different time points could be obtained using mosaic mice with more recombination outcomes than the hemizygous Confetti mice used by Chappell et al. and us. Such tools have recently been published (23).

Several hypotheses can be formed for why only few out of many medial SMCs migrate and proliferate in atherosclerosis. First, the precursors for the SMC clones in plaques might be a special subgroup of medial SMCs with a cell-autonomous propensity for proliferation. The fact that the medial precursor SMCs cells are expressing MYH11, a marker of highly differentiated SMCs, speaks against a less-differentiated progenitor-like population in the media, but it is still possible that there is fixed or fluctuating heterogeneity in the phenotype of medial SMCs, allowing only a minority to partake in atherogenesis at a given point in...
time. Second, clone precursors may have equal endogenous potential to produce plaque SMCs but may be selected by being located at the right place and the right time, e.g., where the barrier of the internal elastic lamina is breached by proteolytic enzyme activity or where a localized signal guides their expansion. Once liberated from the encaging internal elastic lamina (IEL) or modulated by the localized signal, the SMCs are free to proliferate in plaque, leaving still encaged or undisturbed neighbors behind.

Third, one may speculate that few, perhaps randomly chosen, medial SMCs that begin proliferating may actively inhibit their neighbors from taking the same fate. It is a common pattern, often orchestrated by Notch-dependent lateral inhibition signaling, that cells induced to follow a particular fate prevent surrounding cells from doing the same (24). Interestingly, Notch pathways are crucial for SMC recruitment to developing arteries (18, 25), and Notch elements are heavily regulated in modulated SMCs after arterial injury (26).

Different plaque SMC phenotypes. The total abundance of the SMC lineage in atherosclerotic plaques and their modulation to multiple different phenotypes suggest that they may undertake important

Figure 7. The plaque interior accumulates lipid-filled modulated SMCs. (A and B) Serial sections, 200 μm apart, of a plaque at 24 weeks of development showing a large patch of RFP+ SMCs comprising cells with foamy cytoplasm (white arrows point to examples) and also elongated EC-associated cap SMCs (cyan arrows). (C) LGALS3+ cells are present in the plaque (yellow arrows), but no SMCs stain positive for LGALS3. LGALS3 staining was performed with a near-infrared fluorochrome but shown in green for clarity. The section did not contain nGFP+ SMCs. (D) Laser confocal reflection microscopy reveals that some of the accumulating cytoplasmatic material in modulated SMCs is reflective (yellow arrows), consistent with cholesterol crystals. (E–G) Oil Red O staining shows accumulation of neutral lipids in many modulated SMCs. The displayed series of images show an mCFP+ patch of SMCs (E); subsequent Oil Red O staining of the same section (F); and an overlay of the Oil Red O and fluorescent images (G). The inset shows Oil Red O–stained SMCs in higher magnification. L, Lumen. M, Media. Scale bars: 50 μm.
pathophysiological roles in plaque development. This was confirmed by 2 recent studies in which genetic deletion of crucial transcription factors for contractile and modulated SMC phenotypes exerted large effects on plaque progression in Apoe−/− mice (14, 27). However, the spectrum of SMC phenotypes in atherosclerosis, and the pro- or antiatherogenic effector functions that each of these may have, still needs to be identified.

Here, we find that many modulated SMCs in the plaque interior acquired a characteristic foamy cytoplasm and contained neutral lipids. This is consistent with findings in human atherosclerosis of cells double-positive for lipids and ACTA2 (28). Some of the foamy SMCs also contained reflective material, similar in appearance to cholesterol crystals previously reported in plaque macrophages (29). The functional implications for atherogenesis of lipid accumulation and potential cholesterol crystal formation in modulated SMCs would be relevant to test, and the demonstration of these features in the PCSK9-induced mouse atherosclerosis model facilitates such future studies.

Previous analyses of cultured SMCs as well as plaque SMCs in mouse and human plaques have found that modulated SMCs can acquire a macrophage-like cell phenotype, characterized by the expression of proteins that have traditionally been used to identify plaque macrophages, including LGALS3 and CD68 (2, 14, 30). We costained for LGALS3/CD68; however, although cells frequently coexisted in the same regions of lesions, we found no examples of cells that were double-positive for LGALS3/CD68 and one of the Confetti colors. The reason for this apparent discrepancy to previous reports may lie in differences in sensitivity or specificity between staining protocols and image analysis procedures. On one hand, some previous reports have used staining procedures that are probably more sensitive than our standard 2-layer fluorescence protocol (2). On the other hand, our multichannel microscopy makes it easy to distinguish autofluorescence from colocalized tracking and marker signals (Supplemental Figure 3), which can otherwise be a specificity concern. Although there is no a priori reason to think that the type of atherosclerosis model is important, it is also worth noting that previous findings of LGALS3+ and CD68+ SMCs in mouse plaques were all made in the Apoe−/− model.

**Figure 8. Clonally expanded SMCs underlie plaque chondroid metaplasia.** (A and B) Two areas of chondroid metaplasia showing cells with chondrocyte-like morphology (arrows) embedded in a homogeneous matrix staining with the Light Green component of Masson’s trichrome stain (asterisks). (C and D) Fluorescence microscopic analysis of an adjacent section shows that the chondrocyte-like cells are expanded from single cells. (E) Larger magnification of inset in C showing patch with several SMC phenotypes. The YFP+ patch contains not only chondrocyte-like cells (white arrows), but also underlying SMCs with foamy cytoplasm (cyan arrows). (F) Chondrocyte-like SMCs in an adjacent section to that of C with nuclear expression of the chondrogenic transcription factor SOX9 (cyan arrows). Scale bars: 50 μm.
into several different phenotypes and speaking against the idea that medial SMCs are prespecified toward particular fates. The spatial organization of SMC phenotypes with ACTA2+ cells near the endothelium, and foamy and chondrocyte-like SMCs in the plaque interior, indicate that the main controller of SMC phenotypes may be extracellular cues.

Effect of the Confetti transgene on atherosclerosis. The reduction of atherosclerosis in Myh11-CreER
two littermates was unexpected. The 2 groups of mice underwent identical procedures, including tamoxifen injections, pointing directly toward an antiatherogenic role of the Confetti transgene. The Confetti transgene is inserted into the ROSA26 locus and contains neo under the PGK promoter, which—in the absence of recombination — is expressed and blocks transcription of the downstream fluorescent protein genes (15). The antiatherosclerotic effect of the Confetti transgene could therefore be caused by ubiquitous expression of neomycin phosphotransferase, haploinsufficiency of the ROSA26 IncRNAs, the SMC-restricted DNA recombination, or effects of fluorescent protein expression in SMCs. While none of these are obvious candidates for the antiatherosclerotic effect, none of them have, to our knowledge, been directly tested. It would be prudent to clarify this in future studies, since many of these elements are widespread in experimental atherosclerosis research. Although the unexpected effect of the Confetti transgene on atherosclerosis is a limitation of our experiments, the consistency in the results of the aggregation chimeras and Confetti mice argues against a biasing effect on our conclusions on fibrous cap SMC clonality and architecture.

Methods

Embryo aggregation. Apoe–/– mice (B6.129P2-Apoe
Taconic M&B, Taconic Laboratories), which harbor a ROSA26 knock-in of an expression cassette consisting of the CAG promoter, a floxed PGK-Neo–/–pa cassette serving as a transcriptional roadblock, and the Brainbow 2.1 transgene (15). Both lines were extensively backcrossed into B6 mice. Myh11-CreER two littermates was unexpected. The 2 groups of mice underwent identical procedures, including tamoxifen injections, pointing directly toward an antiatherogenic role of the Confetti transgene. The Confetti transgene is inserted into the ROSA26 locus and contains neo under the PGK promoter, which—in the absence of recombination — is expressed and blocks transcription of the downstream fluorescent protein genes (15). The antiatherosclerotic effect of the Confetti transgene could therefore be caused by ubiquitous expression of neomycin phosphotransferase, haploinsufficiency of the ROSA26 IncRNAs, the SMC-restricted DNA recombination, or effects of fluorescent protein expression in SMCs. While none of these are obvious candidates for the antiatherosclerotic effect, none of them have, to our knowledge, been directly tested. It would be prudent to clarify this in future studies, since many of these elements are widespread in experimental atherosclerosis research. Although the unexpected effect of the Confetti transgene on atherosclerosis is a limitation of our experiments, the consistency in the results of the aggregation chimeras and Confetti mice argues against a biasing effect on our conclusions on fibrous cap SMC clonality and architecture.

Multicolor fluorescent transgene experiment. Myh11-CreER two mice (B6.FVB-Tg[Myh11-cre/Ert2]1Soff/J, The Jackson Laboratory), expressing tamoxifen-inducible CRE under the SMC-specific Myh11 promoter (13), were intercrossed with Confetti mice (B6.129P2-Gt[ROSA26]Sortm1[CAG-Brainbow2]Jcr/J, The Jackson Laboratory), which harbor a ROSA26 knock-in of an expression cassette consisting of the CAG promoter, a floxed PGK-Neo–/–pa cassette serving as a transcriptional roadblock, and the Brainbow 2.1 transgene (15). Both lines were extensively backcrossed into B6 mice. Myh11-CreER two Confetti mice (heterozygous for the Confetti knock-in) and Myh11-CreER two littermates were treated with a 10-day series of once-daily 1 mg i.p. injections of tamoxifen (T5648, MilliporeSigma) dissolved in peanut oil from 6–8 weeks of age. Three to 5 days after the last injection, hypercholesterolemia and atherosclerosis was induced by i.v. injection of rAAV8-mD377Y-mPCSK9 virus particles (1 × 10
vector genomes, produced at Vector Core at the University of North Carolina, Chapel Hill, North Carolina, USA) combined with feeding a high-fat diet (D12079B, Research Diets Inc.) containing 21% fat and 0.2% cholesterol as previously described (16). Plasma total cholesterol was measured in duplicate with an enzymatic cholesterol reagent (CHOD-PAP, Roche Diagnostics). Myh11-CreER two Confetti mice and Myh11-CreER two mice were terminated at 12 weeks (n = 18 and n = 8, respectively), 24 weeks (n = 16 and n = 10), and 36 weeks (n = 19 and n = 10) after virus injection. Briefly, mice were anesthetized by i.p. injection of pentobarbital (250 mg/kg) and lidocain (20 mg/kg), perfused with Cardioplex (30 seconds) and 4% phosphate-buffered formaldehyde (5 minutes) at 100 mmHg through the left ventricle, and then immersion-fixed in 4% phosphate-buffered formaldehyde for 6 hours.

Tissue processing and microscopy. The aortic arch and aortic root were cryoprotected in a sucrose solution, embedded in OCT compound, and snap-frozen. Cross-sections of the aortic root were obtained starting from the commissures of the aortic valves until no lesions were present. Serial sections at each approximately 200 μm were washed, DAPI-stained, and mounted for microscopy. The aortic arch was cut longitudinally, and sections near the midline were chosen for analysis. Separate sections from the 24- and 36-week time points were stained for LGALS3, CD68, and SOX9 using rat monoclonal anti-LGALS3 (CedarLane...
Slides from aggregation chimeras were analyzed with an Olympus Cell-R epifluorescence microscope system equipped with differential interference contrast (DIC) optics. Slides from Myh11-CreERT2 Confetti mice were analyzed using a Nikon A1R scanning confocal system coupled to a Nikon Ti-Eclipse microscope with a Pan Fluor ×40/1.3 Oil objective. The entire root was scanned by acquiring multiple images with 3 sequential captures. First, several channels were acquired simultaneously with the 405 nm (DAPI), 488 nm nGFP, 562 nm RFP, and 642 nm (autofluorescence/LGALS3 stain) lasers. Second, mCFP and YFP channels were acquired with 457 nm and 514 nm lasers, respectively. Third, confocal reflection images were obtained to visualize crystals using the 514-nm laser, a beam splitter, and a window of detection of 525–550 nm. All acquisition and postprocessing settings were tested with sections from Myh11-CreERT2 controls to confirm specificity. NIS Elements AR4.30.02 software was used for image acquisition, and ImageJ (NIH) was used for reconstructing total aorta images and to quantify recombination outcomes, plaque volume, number of SMC profiles, and cellularity. Total recombination efficiency and expression of each of the Confetti colors in the arterial media was determined by examining nucleated cells present in the field of view for fluorescence. Plaque volume was calculated by multiplying the average plaque area in serial sections with the total distance of the ascending aorta over which the serial sections were collected. Estimates of the total number of SMCs in plaques were produced by manual counting of fluorescent SMC cellular profiles in plaques (both profiles with and without nucleus present in section). Cellularity of lesions was determined by automatic counting of DAPI-stained nuclei (using a threshold in the DAPI channel followed by particle counting) divided by plaque area.

**Statistics.** Bars in dot plots represent mean ± SEM. P values were calculated using 2-tailed unpaired Student’s t test, one-way ANOVA with Tukey’s post-test, or 2-way ANOVA, as indicated. In some cases, data were log-transformed before analysis. Comparison of distributions of medial SMC colors and patch colors were performed with χ² test. To test whether our data were compatible with the hypothesis that each medial SMC can only produce one plaque SMC phenotype, we calculated the expected number of cases where 2 random fluorescent medial SMCs would produce patches of the same color as $n \sum_{i} x_i^2 / \left( \left( \sum_{i} x_i^2 \right)^2 + \sum_{i} x_i x_j \right)$ and those where 2 random fluorescent medial SMCs would produce patches of different colors as $n \sum_{i} x_i^2 / \left( \left( \sum_{i} x_i^2 \right)^2 + \sum_{i} b_{ij} x_i x_j \right)$, with $n$ being the number of observations and $x_i$ being the fraction of fluorescent medial SMCs with color $i$: $\{\text{mCFP}, \text{nGFP}, \text{YFP}, \text{RFP}\}$. The observed ratio was subsequently compared with the expected ratio using a 2-tailed binomial test. $P < 0.05$ was considered statistically significant. All statistical tests were performed in Prism 6 (GraphPad Software).

**Study approval.** The Danish Animal Experiments Inspectorate approved animal procedures, which were all conducted at Aarhus University (approval no. 2012–15–2934–00286).

**Author contributions**

KJ, MBL, JS, EMF, MK, and JFB designed experiments; KJ, MBL, JS, and SG conducted experiments; KJ, MBL, MK, and LC acquired data; KJ, MBL, LC, and JFB drafted the manuscript; and all authors contributed critically to revision of manuscript.

**Acknowledgments**

The study was funded by grants from the Danish Independent Research Council (Sapere Aude Programme, 4004-00459B) and the Ministerio de Economia, Industria e Competitividad (MEIC) with cofunding from the Fondo Europeo de Desarrollo Regional (FEDER) (SAF2016-75580-R) and by scholarships from the Danish Independent Research Council (to MBL) and the Novo Scholarship Program (to KJ). The CNIC is supported by MEIC and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). We would like to thank Leticia González, Lisa Maria Røge, and Dorte Wilhert Qualm for histology and genotyping; Lisbeth Ahm Hansen and Peter Krøgh for embryo work; the CNIC microscopy Unit (Veronica
Labrador, Elvira Arza, and Antonio Santos-Benit) for support on confocal microscopy; and the CNIC Histopathology Unit (Roisin Doohan, Brenda Guirarro, and Antonio Molina) for histological stainings and tissue scans.

Address correspondence to: Jacob F. Bentzon, Experimental Pathology of Atherosclerosis, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain. Phone: 34.914531200, ext. 2012; Email: jjlbentzon@cnic.es.


